08:09 AM EDT, 07/16/2024 (MT Newswires) -- Conduit Pharmaceuticals ( CDT ) said Tuesday that IP Australia approved its composition of matter patent application for its lead asset, HK-4 glucokinase activator, which targets various autoimmune diseases.

Shares of Conduit surged more than 73% in recent Tuesday premarket activity.

Price: 0.4162, Change: +0.18, Percent Change: +73.42